Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

D. Vrabel, L. Sedlarikova, L. Besse, L. Rihova, R. Bezdekova, M. Almasi, V. Kubaczkova, L. Brožová, J. Jarkovsky, H. Plonkova, T. Jelinek, V. Sandecka, M. Stork, L. Pour, S. Sevcikova, R. Hajek,

. 2020 ; 104 (3) : 190-197. [pub] 20191220

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028432

Grantová podpora
AZV 17-29343A Ministerstvo Zdravotnictví Ceské Republiky

OBJECTIVES: Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. METHODS: While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. RESULTS: We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. CONCLUSIONS: These results support the concept of tumor-specific cell-free DNA as a prognostic marker.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028432
003      
CZ-PrNML
005      
20210114153838.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.13358 $2 doi
035    __
$a (PubMed)31763708
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vrabel, David $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
245    10
$a Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients / $c D. Vrabel, L. Sedlarikova, L. Besse, L. Rihova, R. Bezdekova, M. Almasi, V. Kubaczkova, L. Brožová, J. Jarkovsky, H. Plonkova, T. Jelinek, V. Sandecka, M. Stork, L. Pour, S. Sevcikova, R. Hajek,
520    9_
$a OBJECTIVES: Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. METHODS: While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. RESULTS: We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. CONCLUSIONS: These results support the concept of tumor-specific cell-free DNA as a prognostic marker.
650    12
$a nádorové biomarkery $7 D014408
650    12
$a cirkulující nádorová DNA $7 D000074141
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a management nemoci $7 D019468
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a těžké řetězce imunoglobulinů $x genetika $7 D007143
650    _2
$a mnohočetný myelom $x diagnóza $x genetika $x terapie $7 D009101
650    _2
$a reziduální nádor $x diagnóza $x genetika $7 D018365
650    _2
$a hodnocení výsledků zdravotní péče $7 D017063
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sedlarikova, Lenka $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic.
700    1_
$a Besse, Lenka $u Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Rihova, Lucie $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Bezdekova, Renata $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Almasi, Martina $u Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Kubaczkova, Veronika $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Brožová, Lucie $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Plonkova, Hana $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Jelinek, Tomas $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Sandecka, Viera $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Sevcikova, Sabina $u Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 104, č. 3 (2020), s. 190-197
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31763708 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114153835 $b ABA008
999    __
$a ok $b bmc $g 1608767 $s 1119612
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 104 $c 3 $d 190-197 $e 20191220 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
GRA    __
$a AZV 17-29343A $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace